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Abstract
Background: Oxaliplatin and related chemotherapeutic drugs cause painful chronic peripheral
neuropathies in cancer patients. We investigated changes in neuronal size profiles and
neurofilament immunoreactivity in L5 dorsal root ganglion (DRG) tissue of adult female Wistar rats
after multiple-dose treatment with oxaliplatin, cisplatin, carboplatin or paclitaxel.
Results: After treatment with oxaliplatin, phosphorylated neurofilament heavy subunit (pNF-H)
immunoreactivity was reduced in neuronal cell bodies, but unchanged in nerve fibres, of the L5
DRG. Morphometric analysis confirmed significant changes in the number (-75%; P < 0.0002) and
size (-45%; P < 0.0001) of pNF-H-immunoreactive neurons after oxaliplatin treatment. pNF-H-
immunoreactive neurons had overlapping size profiles and co-localisation with neurons displaying
cell body immunoreactivity for parvalbumin, non-phospho-specific neurofilament medium subunit
(NF-M) and non-phospho-specific neurofilament heavy subunit (NF-H), in control DRG. However,
there were no significant changes in the numbers of neurons with immunoreactivity for
parvalbumin (4.6%, P = 0.82), NF-M (-1%, P = 0.96) or NF-H (0%; P = 0.93) after oxaliplatin
treatment, although the sizes of parvalbumin (-29%, P = 0.047), NF-M (-11%, P = 0.038) and NF-H
(-28%; P = 0.0033) immunoreactive neurons were reduced. In an independent comparison of
different chemotherapeutic agents, the number of pNF-H-immunoreactive neurons was
significantly altered by oxaliplatin (-77.2%; P < 0.0001) and cisplatin (-35.2%; P = 0.03) but not by
carboplatin or paclitaxel, and their mean cell body area was significantly changed by oxaliplatin (-
31.1%; P = 0.008) but not by cisplatin, carboplatin or paclitaxel.
Conclusion: This study has demonstrated a specific pattern of loss of pNF-H immunoreactivity in
rat DRG tissue that corresponds with the relative neurotoxicity of oxaliplatin, cisplatin and
carboplatin. Loss of pNF-H may be mechanistically linked to oxaliplatin-induced neuronal atrophy,
and serves as a readily measureable endpoint of its neurotoxicity in the rat model.
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Background
Oxaliplatin is a platinum-based chemotherapeutic agent
approved for the treatment of colorectal cancer [1].
Although particularly effective for treating colorectal can-
cer, oxaliplatin causes neurotoxicity in a high percentage
of patients [2] that is dose-limiting and can only be pre-
vented by reducing or stopping the drug. Oxaliplatin
causes acute and chronic forms of neurotoxicity in the
clinic. Acute oxaliplatin neurotoxicity presents with
neuro-sensory symptoms that develop during or soon
after each drug infusion then recover within a few days or
weeks [2,3]. These symptoms are exacerbated by cold
exposure and associated with electrophysiological signs of
peripheral nerve hyperexcitability [4]. With repeated treat-
ment, oxaliplatin causes a chronic sensory neuropathy
with distal paraesthesiae and dyesthesiae, loss of tendon
reflexes, vibration sense and proprioception, and sensory
ataxia in severe cases [2,3]. The chronic neurotoxicity of
oxaliplatin is cumulative and less reversible than its acute
syndrome.
There have been previous studies of oxaliplatin-induced
neurotoxicity in rodent models. Single doses of oxalipla-
tin have been reported to acutely disturb nucleolar mor-
phology in DRG neurons [5] and alter behavioural
responses indicating sensory allodynia and hyperalgesia
[6,7]. Chronic oxaliplatin treatment causes reduced sen-
sory nerve conduction in the tail or hind-limb of treated
rodents [8,9], altered sensory responses [10,11] and
changes in the size profiles of DRG neurons [8,9,12] sug-
gestive of neuronal atrophy or the loss of DRG neurons.
The doses of oxaliplatin employed in these previous
rodent studies have varied widely but were often lower
than those used clinically, when expressed as per unit of
body surface area or considered on the basis of relative
systemic exposure achieved in rats [13] and humans [14].
In the current study, we investigated the effect of oxalipla-
tin on neuronal size profiles and neurofilament immuno-
reactivity in DRG tissue from adult Wistar rats following
multiple treatments to a cumulative dose of approxi-
mately 180 mg/m2. This dose was broadly comparable to
those that are achieved clinically [1] and induce changes
in sensory nerve conduction and DRG morphology in the
rat model [8]. Immunohistochemistry was used to iden-
tify subpopulations of DRG neurons and assess their rela-
tive susceptibilities to oxaliplatin-induced neurotoxicity,
as in recent studies [8,15]. The RT97 primary antibody
employed in these studies recognises phosphorylated KSP
repeats in the tail domain of phosphorylated neurofila-
ment heavy subunit (pNF-H) [16]. The epitopes of the
RT97 antibody are strongly expressed in rat DRG tissue
within the cell bodies of subpopulations of large DRG
neurons and large-diameter myelinated nerve fibres [17].
Phosphorylated neurofilaments are major cytoskeletal
proteins of large myelinated sensory neurons [18]. Distur-
bance of neurofilament phosphorylation has been impli-
cated in a wide range of neurodegenerative diseases [19]
but its role in oxaliplatin-induced neurotoxicity is
unknown.
In this paper, we report that neuronal pNF-H expression,
as determined by RT97 immunohistochemistry of rat
DRG tissue, was significantly reduced after oxaliplatin
treatment. This loss of pNF-H immunoreactivity was
shown to correspond with the relative neurotoxicity of
oxaliplatin, cisplatin and carboplatin, but was not associ-
ated with the loss of DRG cells, generalised reduction of
neuronal marker or neurofilament expression, or with
paclitaxel-induced neurotoxicity.
Results
Oxaliplatin-induces loss of neuronal pNF-H 
immunoreactivity
After the treatment of rats with oxaliplatin, pNF-H immu-
noreactivity was reduced in neuronal cell bodies, but
appeared unchanged in nerve fibres, of the L5 DRG (Fig 1
and 2). pNF-H immunohistochemistry was carried out
using the RT97 primary antibody on cryosections of L5
DRG from animals treated with oxaliplatin or 5% glucose
(vehicle control). In control DRG (Figure 1A and 2A),
pNF-H immunoreactivity was associated with ganglionic
nerve fibres and large neuronal cell bodies, with cytoplas-
mic staining and nuclei sparing, consistent with a previ-
ous report [17]. After treatment with oxaliplatin twice
weekly for 8 weeks at a maximum tolerated dose (1.85
mg/kg/dose), pNF-H immunoreactivity of nerve fibres
appeared to be relatively unchanged but that of the DRG
cell bodies was greatly reduced (Figure 1B and 2B). Cell
body size frequency histograms of pNF-H immunoreac-
tive neurons were markedly altered by oxaliplatin treat-
ment (Figure 1C, D).
Morphometric analysis confirmed that oxaliplatin treat-
ment was associated with statistically significant reduc-
tions in the number and size of pNF-H immunoreactive
neurons (Table 1). Defined as DRG neurons with cell
body staining greater than background staining of a nega-
tive control, pNF-H immunoreactive neurons accounted
for approximately 20% of the overall population of DRG
neurons in control animals versus about 5% in animals
treated with oxaliplatin (-75%; P < 0.0002). In addition,
the size of pNF-H-immunoreactive neurons was altered by
oxaliplatin treatment as evident from significant changes
in mean cell body size (-45%, P < 0.0001), and in the per-
centages of neurons with large (>1750 μm2) (-95%; P <
0.001), medium (750-1750 μm2) (-41%; P < 0.0005) or
small cell bodies (<750 μm2) (+247%; P < 0.0001).Molecular Pain 2009, 5:66 http://www.molecularpain.com/content/5/1/66
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Neuronal parvalbumin and non-phospho-specific 
neurofilament immunoreactivity persists following 
oxaliplatin treatment
Next we examined the effect of oxaliplatin on the expres-
sion of parvalbumin, a marker of large DRG neurons. As
previously reported [8,20,21], parvalbumin immunoreac-
tivity in control DRG (Fig 2C) was localized to the cell
bodies of a subset of neurons, whose size profile (Table 1)
was similar to the neuronal subpopulation defined by cell
body immunoreactivity for pNF-H. Double immunofluo-
rescence labeling confirmed extensive co-localization of
parvalbumin and pNF-H immunoreactivity in the neuro-
nal cell bodies of control DRG (Figure 2E). After oxalipla-
tin treatment, parvalbumin immunoreactivity persisted
Loss of neuronal pNF-H immunoreactivity induced by oxaliplatin in rat DRG tissue Figure 1
Loss of neuronal pNF-H immunoreactivity induced by oxaliplatin in rat DRG tissue. Photomicrographs (A, B; mag-
nification: 100×) and cell body size frequency histograms (C, D) of pNF-H-immunoreactive L5 DRG neurons from rats treated 
with the control vehicle (A, C) or oxaliplatin (B, D). Oxaliplatin reduced pNF-H immunostaining of neuronal cell bodies (↑) 
without changing pNF-H immunoreactivity of ganglionic nerve fibers (←). Cell body size frequency histograms of pNF-H-
immunoreactive neurons were altered by oxaliplatin. Bars represent the mean and standard error of the mean for 4 animals.Molecular Pain 2009, 5:66 http://www.molecularpain.com/content/5/1/66
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(Fig 2D) but its co-localization with pNF-H was reduced
(Fig 2F) due to loss of cell body staining of pNF-H (Fig
2B). Morphometric analysis confirmed that the number
of parvalbumin-immunoreactive neurons was not mark-
edly changed (4.6%; NS) by oxaliplatin treatment, but
their size was reduced as evident from significant changes
in their mean cell body area (-29%; P = 0.047) and in the
percentage of large neurons (>1750 μm2) (-81%; P  =
0.008).
Different primary antineurofilament antibodies are
known to vary in their patterns of immunostaining of
DRG due to variation in their affinities for different neu-
rofilament subunits and neurofilament phosphorylation
states [22]. This provided an opportunity to investigate
whether the loss of neuronal RT97 immunoreactivity was
due to a generalised reduction in neurofilament expres-
sion in DRG neurons induced by oxaliplatin. Immunos-
taining with non-phospho-specific antibodies for
neurofilament medium subunit (NF-M) and neurofila-
ment heavy subunit (NF-H) showed no changes in num-
bers of immunoreactive neurons, but did show reductions
in their size profiles, after treatment with oxaliplatin (Fig-
ure 3, Table 1). Non-phospho-specific NF-M immunore-
activity was present in cell bodies of small, medium and
large DRG neurons (Figure 3) accounting for approxi-
mately 40% of the overall neuronal population in L5 DRG
from both control and oxaliplatin-treated animals (-1%; P
= 0.96). However, the mean cell body size of NF-M immu-
noreactive neurons was significantly altered by oxaliplatin
(-11%; P = 0.038). Non-phospho-specific NF-H immuno-
reactivity was present in nerve fibres and many neuronal
cell bodies of all sizes (Figure 3) accounting for >95% of
the overall population of DRG neurons in both control
and oxaliplatin-treated animals (0%; P = 0.93). Consist-
ent with previous reports, relatively intense NF-H staining
was seen in a neuronal subpopulation with large cell bod-
ies, which are known for their high neurofilament content
and myelinated A-type nerve fibres [18]. Although there
was no change in the numbers of NF-H-immunoreactive
neurons, their size was significantly altered by oxaliplatin
as evident by changes in their mean cell body area (-28%;
P = 0.0033), and in the percentages of large (>1750 μm2)
(-76%; P = 0.0003) or small neurons (<750 μm2) (+52%;
P < 0.05).
Comparative effect of chemotherapeutic drugs on 
neuronal pNF-H immunoreactivity
Finally we compared the effect of different chemothera-
peutic agents on neuronal pNF-H immunoreactivity in rat
DRG tissue. Groups of animals were treated for 8 weeks
with multiple-doses of oxaliplatin (1.85 mg/kg/dose
twice per week), cisplatin (1 mg/kg/dose twice per week)
or carboplatin (8 mg/kg/dose twice per week), or for 9
weeks with multiple-doses of paclitaxel (12.5 mg/kg/dose
once per week), or their respective drug vehicles as match-
ing control groups. These doses of oxaliplatin [8,23,24],
cisplatin [24], carboplatin [24] and paclitaxel [25] were
previously shown to alter sensory nerve conduction and
DRG neuronal morphometric parameters in this rat
model in keeping with the induction of a peripheral neu-
ropathy. There was no mortality during the treatment
period but the amount of body weight gained during the
experiment was less in the treatment groups (range; 5 to
17% of baseline) than in the control groups (range; 20 to
27% of baseline). The effect of oxaliplatin on the number
and size of pNF-H-immunoreactive neurons was con-
firmed in this independent experiment. After treatment,
the number of pNF-H-immunoreactive neurons was sig-
nificantly altered by oxaliplatin (-77.2%; P < 0.0001) and
cisplatin (-35.2%; P = 0.003) but not by carboplatin or
paclitaxel (Figure 4A). The mean cell body area of pNF-H-
positive neurons was significantly changed by oxaliplatin
Parvalbumin and pNF-H fluorescent double immunolabelling  of rat DRG tissue from control and oxaliplatin-treated ani- mals Figure 2
Parvalbumin and pNF-H fluorescent double immu-
nolabelling of rat DRG tissue from control and oxali-
platin-treated animals. Representative DRG sections 
displaying fluorescent immunolabelling of pNF-H (FITC; 
green) (A, B) and parvalbumin (Cy3; red) alone (C, D) and 
overlaid to determine the extent of co-expression (yellow) 
(E, F) in L5 DRG of animals treated with the control vehicle 
(A, C, E) or oxaliplatin (B, D, F). Oxaliplatin reduced pNF-H 
cell body staining and its co-localisation with parvalbumin. 
The cell bodies of immunoreactive neurons appeared smaller 
after oxaliplatin. The number of nerve fibres staining for 
pNF-H and cell bodies staining for parvalbumin appeared 
unchanged after oxaliplatin. Magnification = 100×.Molecular Pain 2009, 5:66 http://www.molecularpain.com/content/5/1/66
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(-31.1%; P = 0.008) but not by cisplatin, carboplatin or
paclitaxel (Figure 4B).
Discussion
In this paper we report, for the first time, an effect of oxali-
platin on neurofilament expression in rat DRG tissue as
determined by immunohistochemistry using the RT97
primary anti-neurofilament antibody. The epitopes of the
RT97 antibody are phosphorylated KSP repeats within the
tail domain of phosphorylated neurofilament heavy sub-
unit [16], which are expressed in a specific pattern in DRG
tissue of healthy adult rats [17]. In DRG these epitopes are
expressed within the cell bodies of a subpopulation of
large neurons, presumably during early post-translational
modification of neurofilament subunits, and in their
axons, where neurofilament subunits become hyper-
phosphorylated during their polymerisation into stabi-
lised polymeric complexes [26]. Aberrant neurofilament
phosphorylation, as indicated by altered tissue immuno-
reactivity for phospho-specific anti-neurofilament pri-
mary antibodies, such as the RT97 antibody, has been
associated with other disorders of DRG neurons [27,28],
but a role in oxaliplatin neurotoxicity has not been con-
sidered.
We demonstrated that chronic oxaliplatin treatment was
associated with a specific pattern of loss of pNF-H immu-
noreactivity in rat DRG tissue in the current study. The
loss of pNF-H immunoreactivity was evident visually
from qualitative changes in the intensity of neuronal cell
body immunostaining in DRG sections and by statisti-
cally significant reductions in the numbers and size of
pNF-H-immunoreactive neurons in oxaliplatin-treated
animals, confirmed in two independent experiments.
Strong pNF-H immunoreactivity appeared to remain in
DRG nerve fibres after oxaliplatin treatment indicating
that its loss was specific for the neuronal cell bodies, and
that the treatment caused no nonspecific masking of pNF-
H epitopes, under these experimental conditions. In con-
trol DRG, the neuronal immunoreactivity for pNF-H over-
lapped or colocalised with parvalbumin, non-phospho-
specific-NF-M and non-phospho-specific-NF-H, but the
number of DRG neurons displaying immunoreactivity for
these primary antibodies was not changed by oxaliplatin.
Therefore, the loss of neuronal pNF-H immunoreactivity
was not associated with the loss of DRG cells or any gen-
eralised reduction of neuronal marker or neurofilament
expression induced by oxaliplatin.
The present study also demonstrated that the extent of
loss of pNF-H immunoreactivity corresponded to the rel-
ative neurotoxicity of oxaliplatin, cisplatin and carbopla-
tin. When these platinum agents were ranked according to
their effect on the number of pNF-H-immunoreactive
DRG neurons, oxaliplatin had the greatest effect, followed
by cisplatin and then carboplatin had the least. Their
ranking corresponded with the relative cumulative dose-
potencies of oxaliplatin, cisplatin and carboplatin for
Table 1: Effect of oxaliplatin on morphometry of L5 DRG neurons with immunoreactivity for pNF-H, parvalbumin, NF-M or NF-H.
Frequency of 
Immunoreactive 
Cells (%)
Mean Cell Body 
Area of Immunore-
active Cells (μm2)
Frequency of 
Small Cells (%)
Frequency of 
Medium Cells (%)
Frequency of 
Large Cells (%)
pNF-H Control 21.0 ± 1.9 1259 ± 36 17.2 ± 1.7 67.2 ± 1.8 15.6 ± 2.3
Oxaliplatin 5.2 ± 0.3 696 ± 47 59.7 ± 3.8 39.5 ± 3.3 0.82 ± 0.5
Percent change -75% -45% 247% -41% -95%
P <0.0002 <0.0001 <0.0001 <0.0005 <0.001
Parvalbumin Control 17.4 ± 1.9 1042 ± 31 40.2 ± 1.9 44.6 ± 1.8 15.5 ± 2.9
Oxaliplatin 18.2 ± 4.2 739 ± 75 59.3 ± 12 37.2 ± 5.7 2.9 ± 2.2
Percent change 4.6% -29% 49% -17% -81%
P 0.82 0.047 0.09 0.35 0.008
NF-M Control 41.7 ± 4.0 997 ± 29 32.2 ± 2.2 63.6 ± 3.3 4.2 ± 1.6
Oxaliplatin 41.4 ± 4.6 888 ± 21 39.4 ± 4.5 59.0 ± 4.8 1.6 ± 0.3
Percent change -1% -11% 22% -7% -62%
P 0.96 0.038 0.22 0.47 0.19
NF-H Control 96.0 ± 0.9 1068 ± 42 38.8 ± 6.8 46.0 ± 7.4 15.2 ± 0.8
Oxaliplatin 95.9 ± 1.0 765 ± 24 58.9 ± 1.8 37.4 ± 1.4 3.6 ± 0.6
Percent change 0% -28% 52% -19% -76%
P 0.93 0.0033 0.045 0.32 <0.001
Animals were treated with oxaliplatin or drug vehicle alone (control group) twice per week for 8 weeks. Values represent the mean and standard 
error of the mean for 4 to 5 animals/group.Molecular Pain 2009, 5:66 http://www.molecularpain.com/content/5/1/66
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reducing sensory nerve conduction velocity in rats, which
occurs after cumulative doses of 15, 46.7 and 302 μmol/
kg, respectively [24]. In addition, this ranking corre-
sponded with the proportion of patients developing
peripheral neurotoxicity of any severity grade after treat-
ment with these platinum drugs, which is reported to
occur in ~90% [29], ~50% [30] and ~6% [31] of patients
treated with oxaliplatin, cisplatin and carboplatin, respec-
tively.
These findings link the loss of pNF-H with the neurotox-
icity of oxaliplatin, although its exact role in this toxicity
remains to be elucidated. Phosphorylated neurofilaments
have important physiological roles in maintaining axonal
calibre and fast conduction velocity of large myelinated
nerve fibres [18,26], and their loss causes neuronal and
axonal atrophy, and reduced sensory nerve conduction
velocity, of DRG neurons [32-34]. Therefore, the loss of
neuronal pNF-H expression demonstrated in the current
study may be causally linked to the decreased size profiles
of DRG neurons and reduced sensory nerve conduction
velocity, which are induced by chronic oxaliplatin treat-
ment in rodent models [8,9,12].
The molecular mechanisms responsible for loss of pNF-H
immunoreactivity induced by oxaliplatin are unclear and
require further study. Defects in early neurofilament phos-
phorylation could account for the loss of RT97 cell body
staining without changes in its nerve fibre immunoreac-
tivity or altered immunoreactivity of non-phospho-spe-
cific antineurofilament primary antibodies. The main
pharmacological mechanism of platinum-based drugs is
the formation of platinum-DNA adducts that inhibit DNA
replication and transcription [35]. After exposure to plati-
num drugs, DNA-platinum adducts have been detected in
DRG neurons [36,37] and their level is correlated with the
severity of neurotoxicity [38,39]. Therefore, the loss of
RT97 immunoreactivity could occur due to inhibited tran-
scription of neurofilament kinase genes. However, confir-
mation of a mechanism involving defective
neurofilament phosphorylation or inhibited transcription
would be technically difficult in DRG tissue because of the
confounding effects of persisting RT97 immunoreactivity
of the ganglionic nerve fibres and non-specific inhibition
of DNA transcription by platinum drugs [40]. Whatever
the mechanism, it was evident from this study that pNF-H
is a specific marker of DRG neuronal subpopulations par-
ticularly susceptible to damage from chronic oxaliplatin
exposure, and changes in numbers of pNF-H immunore-
active neurons, are readily measureable endpoints of
oxaliplatin neurotoxicity in the rat. Similarly, the current
study confirmed our previous observations [8] of parval-
bumin being a specific marker of DRG neurons suscepti-
ble to oxaliplatin toxicity and significant changes in size
profiles of parvalbumin immunoreactive neurons during
this neurotoxicity. Detecting oxaliplatin-induced neuro-
toxicity in the rat model using pNF-H or parvalbumin
immunohistochemistry is statistically more powerful and
utilises fewer animals than nerve conduction studies.
However, unlike immunochemical endpoints, nerve con-
duction measurements can be repeated at different times
in the same animal and provide functional information.
Paclitaxel causes peripheral neurotoxicity in a high pro-
portion of treated patients [41] and reductions in sensory
nerve conduction velocity in the rat [25,42-44], but had
no effect on the number or size of pNF-H immunoreactive
neurons in this study. The mechanism of paclitaxel neuro-
toxicity may involve microtubule binding and distur-
bance of microtubule polymerisation with resulting
axonal damage [43,45] and secondary reactive changes in
DRG cell bodies [25,46,47]. In contrast, the mechanism
of oxaliplatin neurotoxicity may involve a loss of phos-
phorylated neurofilaments at the level of DRG cell bodies
with secondary changes in axonal calibre and conduction
velocity. In this way, disturbance of major neuronal
cytoskeletal proteins, such as microtubules and neurofila-
ments, may be a common mechanistic theme whereby
Non-phospho-specific neurofilament immunoreactivity of rat  DRG tissue Figure 3
Non-phospho-specific neurofilament immunoreactiv-
ity of rat DRG tissue. Immunohistochemistry using non-
phospho-specific primary antibodies for NF-M and NF-H in 
representative sections of DRG from control and oxaliplatin 
treated animals. Oxaliplatin did not change the numbers of 
immunoreactive neurons but reduced their size.
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different anticancer drugs from various classes damage the
peripheral nervous system.
Conclusion
In conclusion, this study has demonstrated a specific pat-
tern of loss of pNF-H immunoreactivity in rat DRG tissue
that corresponds with the relative neurotoxicity of oxalipl-
atin, cisplatin and carboplatin. Loss of pNF-H may be
mechanistically linked to oxaliplatin-induced neuronal
atrophy and serves as readily measureable endpoints of
oxaliplatin neurotoxicity in the rat model.
Methods
Animals and Drugs
Age-matched 10-week old female Wistar rats were used for
experiments that weighed approximately 270 g at the
commencement of the study. All animals were housed in
a temperature and humidity-controlled environment with
uninhibited access to food and water. Oxaliplatin (Sigma-
Aldrich, St. Louis, MO, USA and Sanofi-Synthelabo NZ
Ltd, Auckland, NZ) and carboplatin (Mayne Pharma, Vic,
Australia) were diluted for injection in 5% dextrose (Bax-
ter Healthcare, Old Toongabbie, Australia) for intraperito-
neal injection at 15 ml/kg. Cisplatin (Sigma) was diluted
in 0.9% sodium chloride (Baxter Healthcare) for intra-
peritoneal injection at 15 ml/kg. Paclitaxel (Phytogen Life
Sciences Inc., Delta, BC, Canada) was solubilised in a 1:1
solution of Cremophor EL (Sigma-Aldrich) and ethanol
to make a stock solution of 6 mg/ml, then further diluted
with 0.9% NaCl (Baxter Healthcare) for administration by
intraperitoneal injection at an injection volume of 12.5
ml/kg. Animals were treated twice per week either with
oxaliplatin (1.85 mg/kg), carboplatin (8 mg/kg) or their
control drug vehicle of 5% dextrose, or with cisplatin (1
mg/kg) or its control vehicle of 0.9% sodium chloride, an
injection volume of 15 ml/kg for 8 weeks. Paclitaxel-
treated animals received 12.5 mg/kg of drug once weekly
for a total of 9 weeks, and control animals were treated
with the Cremophor EL/ethanol/0.9% NaCl solution at
the same dosing frequency and injection volume. To pre-
vent time-dependent variation in pharmacokinetics and
pharmacodynamics all injections were performed
between 1 and 3 p.m. The Animal Ethics Committee of
the University of Auckland approved all animal proce-
dures.
Single-label Immunohistochemistry
One week after the conclusion of treatment, terminal
anaesthesia was induced by administering 0.9 ml of 3 mg/
ml pentobarbitone (Chemstock Animal Health Ltd,
Christchurch, New Zealand). Subsequently, transcardiac
perfusion with 60 ml of 0.9% NaCl (Baxter Healthcare)
followed by 60 ml of 4% paraformaldehyde in 0.1 M
phosphate buffer was carried out. L5 DRGs were carefully
dissected from each animal, post-fixed in 4% paraformal-
dehyde for 2-6 hours and cryoprotected in a 30% sucrose
solution until the tissues sunk. Following cryoprotection,
the DRG were placed in Tissue-Tek OCT compound
(Sakura Finetek, Torrance, CA, USA), snap frozen in liquid
nitrogen and stored at -80°C. Each dorsal root ganglion
was sectioned on a cryostat (Leica CM 3050) at a thickness
of 10 μm onto polylysine-coated slides that were then
stored at -80°C. For immunostaining, frozen tissue slides
were warmed to room temperature, washed in PBS con-
taining 0.2% Triton X-100 and incubated in 1% H2O2 in
50% methanol for 10 minutes. To prevent non-specific
Comparative effect of anticancer drugs on neuronal pNF-H  immunoreactivity Figure 4
Comparative effect of anticancer drugs on neuronal 
pNF-H immunoreactivity. DRG were analysed after mul-
tiple-dose treatment with maximally tolerated doses of oxali-
platin (Oxal; 1.85 mg/kg/dose twice per week for 8 weeks), 
cisplatin (Cispl; 1 mg/kg/dose twice per week per 8 weeks), 
carboplatin (Carb; 8 mg/kg/dose twice per week per 8 
weeks) and paclitaxel (Pacl; 12.5 mg/kg/dose once per week 
for 9 weeks). Bars represent the mean and standard devia-
tion of 3 to 6 animals, * P < 0.01.
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binding, the slides were blocked for 1 hour in PBS con-
taining 0.2% Triton X-100 with 3% normal goat serum
(Sigma-Aldrich) and 20 mg/ml bovine serum albumin
(Sigma-Aldrich). Next, the slides were incubated over-
night in a humidity chamber with either the mouse mon-
oclonal antibody to the phospho-specific NF-H subunit
(RT-97 clone; 1:100; CBL212, Chemicon International,
Temecula, CA, USA), rabbit polyclonal anti-parvalbumin
(PVA3) primary antibody (1:1000; P. Emson, Cambridge,
UK), rabbit polyclonal non-phospho-specific antineuro-
filament 200 IgG fraction (1:1000; Sigma N4142) or
mouse monoclonal non-phospho-specific antineurofila-
ment medium subunit (1:1000; Sigma N5264). The slides
were rewashed and incubated with either an anti-mouse
or anti-rabbit biotinylated secondary antibody (1:500;
Sigma-Aldrich) for 2.5 hours. After further washes, the
slides were incubated for 3 hours in an extravidin-peroxi-
dase conjugate (1:500; Sigma-Aldrich). Staining was visu-
alised with 0.5 mg/ml 3,3'-diaminobenzidine
tetrahydrochloride (AppliChem, Darmstadt, Germany)
and 0.01% H2O2 in 0.4 M phosphate buffer for 10 min-
utes. Finally, the slides were washed, dehydrated through
a series of alcohols, cleared in xylene and coverslipped.
The DRG sections were analysed by light microscopy with
digital images generated by an Axiocam camera (Carl
Zeiss Vision, Hallbergmoos, Germany) and quantitative
analysis performed using AxioVision 3.0 (Carl Zeiss Soft-
ware) software. The cross-sectional area was measured for
each immunoreactive neuron and the frequency of expres-
sion was generated by counting every cell and expressing
the count of immunoreactive neurons as a percentage of
the total cell count. Immunoreactive DRG neurons were
also categorised on the basis of size into small (cross-sec-
tional area <750 μm2), medium (750-1750 μm2) and
large (>1750 μm2) sized cells.
Fluorescent Double Labelling Immunohistochemistry
Frozen DRG slides were defrosted, washed, incubated in
H2O2 with methanol and blocked as described previously
for single-label immunohistochemistry. Each slide was
incubated overnight in a humidity chamber in both
mouse anti-pNF-H (1:100) and rabbit anti-parvalbumin
(1:1000) primary antibodies. The slides were then washed
and incubated in the dark for 4 hours in both anti-rabbit
cy3 (1:200; Jackson Laboratories, West Grove, PA, USA)
and biotinylated anti-mouse secondary antibodies
(1:200, Sigma). The slides were rewashed and incubated
in the dark for 3 hours in FITC tertiary antibody (1:200;
Sigma-Aldrich). Finally, the slides were washed, cover
slipped with Citifluor (Agar Scientific, Essex, UK) and
stored overnight at 4°C to prevent bleaching. Fluorescent
analysis was performed with a Zeiss Axioplan 2 epifluo-
rescence microscope (Carl Zeiss Microscopy) equipped
with fluorescent rhodamine and FITC filters with excita-
tion wavelength ranges of 534-558 nm and 450-490 nm,
respectively. Monochrome images were captured by a
Dage video camera (Newvicom, Wiesbaden, Germany)
and were converted to pseudo-coloured images by Meta-
morph 6.1 software (Universal Imaging Corporation,
Downington, PA, USA).
Statistics
The statistical significance of differences in means
between treatment and control groups were assessed
using unpaired t-tests and analysis of variance (ANOVA).
P values < 0.05 indicated statistical significance.
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